Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications
NCT ID: NCT01681407
Last Updated: 2015-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
17 participants
OBSERVATIONAL
2011-11-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
NCT00048607
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients
NCT01237275
MRS and Medication Response: A Pilot Study
NCT03254342
Combining Medications to Enhance Depression Outcomes
NCT00590863
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
NCT00035048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depressed Patients
Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
No interventions assigned to this group
Non-Depressed Controls
Controls: Volunteers that had clinical screening with no depression diagnosis.
No interventions assigned to this group
Patients Relatives
Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Untreated with SSRI, in the last 3 months
Exclusion Criteria
* Depressive disorder clearly due to general medical condition, or drug related
* BMI under 18.5 or above 40
* Pregnant patients
* Active suicidality
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amichai Hareven
Dr Amichai Hareven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HaEmek Medical Center
Afula, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMC-07411-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.